TScan Therapeutics Announces Positive Updated Data from the ALLOHA™ Phase 1 Heme Trial at the 67th American Society of Hematology Annual Meeting and Exposition

TScan Therapeutics Announces Positive Updated Data from the ALLOHA™ Phase 1 Heme Trial at the 67th American Society of Hematology Annual Meeting and Exposition

By

TScan Therapeutics to Host Virtual KOL Event to Discuss Clinical Updates from the ALLOHA™ Phase 1 Trial and Future Market Opportunities

By

TScan Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

By

TScan Therapeutics to Participate in the Guggenheim 2nd Annual Healthcare Innovation Conference

By

TScan Therapeutics Reaches Agreement with FDA on Pivotal Study Design for TSC-101 and Announces Strategic Prioritization to Advance TSC-101 and Extend Cash Runway into H2 2027

By

TScan Therapeutics Announces Upcoming Oral and Poster Presentations at the American College of Rheumatology Convergence 2025

By

TScan Therapeutics to Participate in Upcoming Investor Conferences

By

TScan Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

By

TScan Therapeutics Announces Upcoming Presentation at the Jefferies Global Healthcare Conference

By

TScan Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

By